Genetic Engineering-Based Target Screening

Genetic engineering is a powerful tool for screening and validating drug targets. Ace Therapeutics uses a variety of technology platforms and live animal models to help global customers screen and validate potential targets for ophthalmic drugs. Based on our most complete zebrafish living animal model, our scientists meet the needs of many customers' ophthalmic research through a variety of genetic manipulation methods.

Genetic Engineering & Target Screening and Validation

Genetic engineering, also known as genetic modification or gene editing, is the process of changing the genetic structure of an organism by adding, deleting, or in situ modifying existing genetic material at specific locations in the genome. Currently, gene editing is widely used in cell and animal models in research laboratories to understand eye disease, thereby identifying and validating new biological targets for precision medicine. It provides a fast and unbiased way to elucidate how the genome influences phenotypes, with implications for the prevention and treatment of human eye disease.

Genetic Engineering-Based Target Screening

Services Overview

Ace Therapeutics has a team of experts who have achieved outstanding results in the field of genetic engineering. With the help of genetic engineering technology, they have successfully achieved commendable results for our customers in the target identification and verification phase of ophthalmic drugs.

At Ace Therapeutics, our scientists offer a range of genetic manipulation solutions to meet the needs of your research, including viable solutions for every stage of genetic manipulation. What attracts our clients is that our experienced researchers use optimized and proven technical systems to minimize and eliminate possible trial and error phases. This results in ideal answers in faster time and with fewer errors.

Explore Our Gene Editing Services

Genetic Engineering-Based Target Screening

Gene Knockout

Genetic screens in zebrafish are powerful tools for exploring the mechanisms underlying vertebrate development, tissue biology, physiology, and disease. Our geneticists have established a complete zebrafish platform for the study of eye diseases, and the CRISPR/Cas9 system is our most proud technology platform. Relying on the zebrafish platform and the CRISPR/Cas9 system, our scientists can infer how gene function is at work by comparing differences between knockout organisms and normal individuals. This helps clients accelerate the identification and validation of high-value targets, discover high-confidence biomarkers, and develop differentiated breakthrough therapies, fully meeting their project requirements and budgets for gene knockout services.

Genetic Engineering-Based Target Screening

RNAi-Mediated Gene Silencing

Publication of the human eye genome has increased research into gene and protein expression analysis. With the help of RNAi-mediated gene silencing technology, Ace Therapeutics is expected to evaluate many functional genes related to ophthalmic diseases. Small interfering RNA (siRNA) is known to silence the expression of target genes in a sequence-specific manner in mammalian cells. Our team of scientists has developed systems for vector-mediated specific RNAi. Vector-based siRNA (or shRNA) expression libraries and chemically synthesized oligonucleotide-based siRNA libraries targeting the entire human ocular genome now allow rapid identification of functional genes and potential drug targets for ophthalmic diseases. For many years, Ace Therapeutics has been developing technologies and providing services for drug discovery and target validation through gene silencing.

Gene Overexpression

Overexpression of gene products can lead to mutant phenotypes, providing geneticists with a powerful tool to identify novel pathway components that are undetected using traditional loss-of-function assays. Relying on an increasingly accurate gene expression database and powerful bioinformatics tools, Ace Therapeutics has expanded new strategies for ophthalmic drug targets discovery. Our scientists have provided new ideas for ophthalmic drug discovery with the help of gene overexpression strategies.

Genetic Engineering-Based Target Screening

Gene Conditional Expression

Genetic mutations are crucial to determining the stage- and tissue-specific functions of genes. Ace Therapeutics uses the zebrafish and rodent living models to carry out stage- and tissue-specific rescue or knockout of mutant genes, which is helpful for systematic and large-scale ocular gene identification and validation. With targeted conditional overexpression, our scientists help customers identify potential drug targets as well as develop personalized live animal models based on eye disease-related mutant genes.

Benefit from our comprehensive，systematic gene editing platform and live animal models. Ace Therapeutics is pleased to provide technical support for global customers' ophthalmology research. Our geneticists have achieved milestones in the field of target discovery for ophthalmic drugs with the help of gene editing technology. If you are interested in our services or have special needs, please feel free to contact us. We look forward to working with you in the future.

For Research Use Only.

Get in Touch